4D Molecular Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $-73.0M | $49.7M |
| FY2020 | — | $256.4M | $276.7M |
| FY2021 | — | $319.1M | $153.0M |
| FY2022 | — | $231.3M | $52.4M |
| FY2023 | — | $307.8M | $249.1M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $-73.0M | $49.7M |
| FY2020 | — | $256.4M | $276.7M |
| FY2021 | — | $319.1M | $153.0M |
| FY2022 | — | $231.3M | $52.4M |
| FY2023 | — | $307.8M | $249.1M |